Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Grows By 21.5%

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) saw a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 1,983,177 shares, an increase of 21.5% from the January 15th total of 1,632,436 shares. Based on an average trading volume of 2,033,323 shares, the days-to-cover ratio is currently 1.0 days. Approximately 7.9% of the shares of the company are short sold. Approximately 7.9% of the shares of the company are short sold. Based on an average trading volume of 2,033,323 shares, the days-to-cover ratio is currently 1.0 days.

Insider Buying and Selling at MAIA Biotechnology

In other MAIA Biotechnology news, Director Stan Smith bought 57,189 shares of the stock in a transaction on Monday, December 22nd. The shares were acquired at an average price of $1.22 per share, with a total value of $69,770.58. Following the acquisition, the director directly owned 1,421,478 shares of the company’s stock, valued at $1,734,203.16. The trade was a 4.19% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Steven M. Chaouki purchased 40,849 shares of MAIA Biotechnology stock in a transaction dated Monday, December 22nd. The stock was bought at an average price of $1.22 per share, with a total value of $49,835.78. Following the completion of the transaction, the director owned 151,873 shares of the company’s stock, valued at $185,285.06. This represents a 36.79% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 349,122 shares of company stock worth $402,193 over the last three months. Company insiders own 32.32% of the company’s stock.

Institutional Investors Weigh In On MAIA Biotechnology

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Centerpoint Advisory Group bought a new stake in shares of MAIA Biotechnology during the 2nd quarter valued at about $28,000. Marshall Wace LLP purchased a new position in MAIA Biotechnology in the 2nd quarter worth $29,000. Ritholtz Wealth Management bought a new stake in MAIA Biotechnology in the fourth quarter worth $35,000. Jane Street Group LLC purchased a new stake in MAIA Biotechnology during the second quarter valued at about $52,000. Finally, Geode Capital Management LLC grew its stake in shares of MAIA Biotechnology by 3.6% during the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after buying an additional 7,746 shares during the last quarter. Hedge funds and other institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Stock Down 2.5%

Shares of MAIA opened at $1.92 on Tuesday. MAIA Biotechnology has a twelve month low of $0.87 and a twelve month high of $3.19. The stock has a market cap of $71.10 million, a PE ratio of -2.63 and a beta of -0.07. The business’s 50-day moving average price is $1.77 and its 200-day moving average price is $1.54.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.